UI Investissement
UI Investissement, formerly known as UI Gestion SAS, is a private equity and venture capital firm established in 2004 and headquartered in Paris, France. The firm specializes in investments in small to mid-cap companies across various sectors, with a particular focus on healthcare, agri-food, and services industries. Over the years, UI Investissement has actively supported the growth of more than 120 small and medium-sized enterprises, investing over €550 million in their development projects. The firm aims to finance a wide range of business stages, including seed, startup, and growth capital, as well as buyouts and turnaround transactions. Its investment strategy is regionally focused, primarily targeting areas in France such as Aquitaine, Brittany, and Ile-de-France, and it typically invests between €1 million and €50 million depending on the enterprise value of the companies. UI Investissement aims to act as both a majority and minority shareholder, leveraging its experience and corporate culture to foster sustainable performance in its portfolio companies.
AdEchoTech
Venture Round in 2024
AdEchoTech is a French company based near Paris, founded in 2008 by Dr. Éric Lefebvre, an experienced ultrasound radiologist. The company focuses on developing remote ultrasonography devices to address medical desertification and the shortage of healthcare services in underserved areas. AdEchoTech specializes in the design, manufacture, and marketing of robotic ultrasound equipment for various medical applications, including abdominal, cardiac, pelvic, urinary tract, and gynecologic care. By incorporating input from the medical community during the design process, AdEchoTech ensures that its solutions effectively meet the needs of healthcare providers and improve patient care. The company's innovations aim to reduce transportation costs and enhance the availability of sonographers, ultimately contributing to better public health outcomes.
Acticor Biotech
Post in 2024
Acticor Biotech is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the urgent need for effective therapies in the acute phase of ischemic stroke, a condition that affects approximately 15 million people globally each year, leading to significant mortality and disability. Currently, there is a lack of effective treatment options, with existing therapies demonstrating limited efficacy and accessibility. Acticor Biotech seeks to provide innovative solutions to improve outcomes for stroke patients, addressing a critical gap in current medical care.
Geosophy
Venture Round in 2023
Geosophy, founded in 2018 and based in Paris, France, specializes in developing real estate assets while managing energy consumption to ensure local thermal comfort. The company creates software tools designed to evaluate the geo-energy potential for sustainable heating and cooling solutions for buildings. Utilizing data science and machine learning techniques, Geosophy's tools facilitate the development of physics and financial models that automate and enhance feasibility studies for geo-energy installations. This enables building owners to effectively leverage their geo-energy resources, thus contributing to value creation in the real estate sector.
Cocolis
Private Equity Round in 2021
Cocolis is a Paris-based company established in 2015 that specializes in online shipping solutions for heavy or bulky items. The platform connects individuals or businesses needing to send parcels with drivers who have available space in their vehicles. By utilizing this co-transportation model, Cocolis offers a cost-effective alternative for shipping, allowing users to reduce their shipping expenses or receive partial reimbursement for transport costs. This innovative approach facilitates efficient logistics while promoting the use of empty vehicle capacity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.